Skip to main content
. 2018 Mar 20;25(1):815–826. doi: 10.1080/10717544.2018.1451572

Table 3.

Skin permeability parameters of DCN after topical application of E1, DCN-loaded bilosomes, and drug suspension (A) and pharmacokinetic parameters of E1 in comparison with DCN oral suspension (B).

(A) Treatment  
 Skin permeability parameters E1 DCN-loaded bilosomes Drug suspension
 Total amount of drug permeated per unit area in 24 h (µg/cm2)a 1150.92 ± 194.71 1003.50 ± 47.38 59.44 ± 0.50
Jmax (µg/cm2/h)a 27.24 ± 4.61 23.75 ± 1.12 1.41 ± 0.01
 ER 19.36 16.84 1
(B)
In-vivo pharmacokinetic parameters E1   DCN oral suspension
Cmax (µg/mL)b 0.76 ± 0.04   2.24 ± 1.12
Tmax (h)c 1   1
 AUC0→24 (µg h/mL)b 9.26 ± 3.02   9.95 ± 1.04
 AUC0→∞ (µg h/mL)b 20.65 ± 16.40   15.49 ± 10.04

Jmax: flux; ER: enhancement ratio.

a

Data presented as mean ± SD (n = 3).

b

Data presented as mean ± SD (n = 6).

c

Data presented as median.